BIORETEC OY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.61 EUR | +1.95% |
|
-2.25% | +8.75% |
| 04-05 | Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors | CI |
| 03-22 | Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition | MT |
| Sales 2023 | 3.91M 4.2M 335M | Sales 2024 * | 5.9M 6.35M 506M | Capitalization | 53.08M 57.12M 4.56B |
|---|---|---|---|---|---|
| Net income 2023 | -3M -3.23M -257M | Net income 2024 * | -3M -3.23M -257M | EV / Sales 2023 | 13.6 x |
| Net cash position 2023 * | 5.8M 6.24M 498M | Net cash position 2024 * | 1.6M 1.72M 137M | EV / Sales 2024 * | 8.73 x |
| P/E ratio 2023 |
-13.7
x | P/E ratio 2024 * |
-17.4
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 64.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.95% | ||
| 1 week | -2.25% | ||
| Current month | +0.77% | ||
| 1 month | -4.74% | ||
| 3 months | +10.13% | ||
| 6 months | +6.97% | ||
| Current year | +8.75% |
1 week
2.49
2.67
1 month
2.492.90
Current year
2.142.90
1 year
2.022.90
3 years
1.253.75
5 years
1.253.75
10 years
1.253.75
| Managers | Title | Age | Since |
|---|---|---|---|
Timo Lehtonen
CEO | Chief Executive Officer | 49 | 28/02/19 |
| Director of Finance/CFO | 57 | 31/01/21 | |
| Chairman | 53 | 30/04/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 53 | 30/04/16 | |
| Director/Board Member | 50 | 31/12/19 | |
| Director/Board Member | 65 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 2.61 | +1.95% | 33,510 |
| 02/05/24 | 2.56 | -1.16% | 23,306 |
| 30/04/24 | 2.59 | -1.52% | 10,565 |
| 29/04/24 | 2.63 | -1.50% | 18,025 |
| 26/04/24 | 2.67 | +0.75% | 8,190 |
Delayed Quote Nasdaq Helsinki, May 03, 2024 at 04:20 pm
More quotes
Bioretec Oy is a Finland-based medical device manufacturer company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The Company operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oyâs existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Companyâs products are used all over the world.
Calendar
15/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.61
EUR
Average target price
3.75
EUR
Spread / Average Target
+43.68%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.75% | 55.7M | |
| +73.37% | 12.38B | |
| -17.09% | 7.99B | |
| +16.88% | 7.21B | |
| +3.57% | 5.79B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.74% | 4.17B | |
| -35.26% | 2.44B | |
| +3.09% | 2.03B |
- Stock Market
- Equities
- BRETEC Stock
